No. | 5-FU | PRI-2191 | TGI [%] | ILS [%] | Maximal decrease |
---|
in body weight [%] |
---|
5-FU | PRI-2191 | 5-FU+ | %H TGI | Effect | 5-FU | PRI-2191 | 5-FU+ | %H ILS | Effect | 5-FU | PRI-2191 | 5-FU+ |
---|
PRI-2191 | PRI-2191 | PRI-2191 |
---|
1 | 75 mg/kg; | 2 μg/kg | 48 | 6 | 70*
| 51 | Synergism | 21 | 53 | 41 | 62 | Antagonism | 7 | 18 | 19 |
2 | 150 mg/kg; | 2 μg/kg | 87 | 44 | 96*
| 92 | Synergism | nt. | nt. | nt. | nt. | nt. | 9 | 11 | 21 |
3 | 100 mg/kg; | 1 μg/kg | 38 | 6 | 51 | 42 | Synergism | 26 | -6 | 118*a
| 22 | Synergism | 4 | 6 | 12 |
4 | 100 mg/kg; | 0.5 μg/kg | 38 | 1 | 36 | 39 | Antagonism | 26 | -6 | 43 | 22 | Synergism | 4 | 3 | 9 |
5 | 100 mg/kg; | 0.25 μg/kg | 38 | -35 | 36 | 16 | Antagonism | 26 | 3 | 65 | 29 | Synergism | 4 | 9 | 9 |
- Vitamin D analog was administered subcutaneously, three times a week.
- No. – number of experiment; TGI – tumor growth inhibition; %H TGI: hypothetical tumor growth inhibition; ILS: increase in life span; %H ILS: hypothetical increase in life span; nt.: not tested; No. 1 – TGI calculated on the 27th day of the experiment, No. 2, 3, 4, 5 – TGI on the 32nd day of the experiment.
- No. 1: 5-FU was injected i.p. on the first day; PRI-2191 was injected on days: 1, 3, 6, 8, 10, 13, 15, 17, 20, 22; Number of mice: control - 10; in the each treatment group - 8.
- No. 2: 5-FU was injected i.p. on days: 9, 16, 23; PRI-2191 was injected on days: 11, 14, 16, 18, 21, 23; Number of mice in each group - 8.
- No. 3, 4 and 5: 5-FU was injected i.v. on days: 8, 15, 30, 38; PRI-2191 was injected on days: 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44; Number of mice: No. 3, 4 and 5: control – 7; 5-FU – 7, PRI-2191 – 5; 5-FU + PRI-2191 – 6; *
P < 0.05 as compared to control; *a
P < 0.05 as compared to 5-FU.